These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 31902930)

  • 1. State of the Art: Development of a Sublingual Allergy Immunotherapy Tablet for Allergic Rhinitis in Japan.
    Ohashi-Doi K; Lund K; Mitobe Y; Okamiya K
    Biol Pharm Bull; 2020; 43(1):41-48. PubMed ID: 31902930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
    Meteran H; Backer V
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study.
    Contoli M; Porsbjerg C; Buchs S; Larsen JR; Freemantle N; Fritzsching B
    J Allergy Clin Immunol; 2023 Aug; 152(2):445-452.e4. PubMed ID: 36871918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases.
    Nolte H; Maloney J
    Allergol Int; 2018 Jul; 67(3):301-308. PubMed ID: 29759659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergen Stability and Immunological Reactivity during Co-dissolution and Incubation of House Dust Mite and Japanese Cedar Pollen SLIT-Tablets.
    Watanabe A; Yamamoto T; Matsuhara H; Matsui H; Nakazawa H; Lund K; Ohashi-Doi K
    Biol Pharm Bull; 2020 Oct; 43(10):1448-1450. PubMed ID: 32759600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.
    Brunton S; Nelson HS; Bernstein DI; Lawton S; Lu S; Nolte H
    Postgrad Med; 2017 Aug; 129(6):581-589. PubMed ID: 28326908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of sublingual immunotherapy for allergic rhinitis in Japan.
    Masuyama K; Matsuoka T; Kamijo A
    Allergol Int; 2018 Jul; 67(3):320-325. PubMed ID: 29805085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma.
    Creticos PS; Gunaydin FE; Nolte H; Damask C; Durham SR
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1415-1427. PubMed ID: 38685477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet.
    Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y
    Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.
    Rønborg S; Johnsen CR; Theilgaard S; Winther A; Hahn-Pedersen J; Andreasen JN; Olsen J
    J Med Econ; 2016 Aug; 19(8):735-41. PubMed ID: 26909663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Developmental history of sublingual immunotherapy].
    Du W; Maekawa Y; Natsui K
    Nihon Yakurigaku Zasshi; 2019; 154(1):6-11. PubMed ID: 31308350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
    Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
    Front Immunol; 2021; 12():723814. PubMed ID: 34721385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.
    Klimek L; Mosbech H; Zieglmayer P; Rehm D; Stage BS; Demoly P
    Expert Rev Clin Immunol; 2016; 12(4):369-77. PubMed ID: 26788764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
    Vitiello G; Maltagliati L; Rossi O
    Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
    Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.